OSR Holdings, Inc. (NASDAQ:OSRH) Sees Large Growth in Short Interest

OSR Holdings, Inc. (NASDAQ:OSRH) was the target of a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 376,966 shares, a growth of 42.8% from the February 26th total of 264,011 shares. Based on an average daily volume of 523,223 shares, the days-to-cover ratio is currently 0.7 days. Approximately 3.7% of the shares of the company are sold short.

Institutional Trading of OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP purchased a new stake in OSR Holdings, Inc. (NASDAQ:OSRH) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR at the end of the most recent reporting period. Institutional investors and hedge funds own 55.30% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of OSR in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, OSR currently has an average rating of “Sell”.

OSR Trading Up 5.6%

OSRH stock traded up $0.02 during mid-day trading on Friday, hitting $0.46. 3,114,662 shares of the company were exchanged, compared to its average volume of 891,391. The business has a 50 day simple moving average of $0.51 and a 200-day simple moving average of $0.59. The stock has a market capitalization of $11.93 million, a PE ratio of -0.41 and a beta of 1.54. OSR has a 1-year low of $0.38 and a 1-year high of $3.30.

OSR Company Profile

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.